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Abstract
Genetic and biochemical studies support the apolipoprotein E (APOE) ε4 allele as a major risk factor
for late-onset Alzheimer's disease (AD), though ~50% of AD patients do not carry the allele. APOE
transports cholesterol for luteinizing hormone (LH)-regulated steroidogenesis, and both LH and
neurosteroids have been implicated in the etiology of AD. Since polymorphisms of LH beta-subunit
(LHB) and its receptor (LHCGR) have not been tested for their association with AD, we scored AD
and age-matched control samples for APOE genotype and 14 polymorphisms of LHB and LHCGR.
Thirteen gene-gene interactions between the loci of LHB, LHCGR, and APOE were associated with
AD. The most strongly supported of these interactions was between an LHCGR  intronic
polymorphism (rs4073366; lhcgr2) and APOE  in males, which was detected using all three
interaction analyses: linkage disequilibrium, multi-dimensionality reduction, and logistic regression.
While the APOE ε4 allele carried significant risk of AD in males [p = 0.007, odds ratio (OR) =
3.08(95%confidence interval: 1.37, 6.91)], ε4-positive males carrying 1 or 2 C-alleles at lhcgr2
exhibited significantly decreased risk of AD [OR = 0.06(0.01, 0.38); p = 0.003]. This suggests that
the lhcgr2 C-allele or a closely linked locus greatly reduces the risk of AD in males carrying an APOE
ε4 allele. The reversal of risk embodied in this interaction powerfully supports the importance of
considering the role gene-gene interactions play in the etiology of complex biological diseases and
demonstrates the importance of using multiple analytic methods to detect well-supported gene-
gene interactions.
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Background
Alzheimer's disease (AD) is a progressive neurodegenera-
tive disorder characterized by neuronal and synaptic loss,
neurofibrillary tangles in neuronal cytoplasm, and depo-
sition of β-amyloid (Aβ) in extracellular, neuritic plaques.
To date, only four genes have been unambiguously asso-
ciated with AD, of which only one, Apolipoprotein E
(APOE), is associated with the common, late-onset form
of AD [1]. The APOE4 allele (ε4) was first identified as a
risk factor for late-onset AD in the early 1990s [2,3], and
corroborated as such by a number of subsequent studies
[4]. However, the risk for AD imparted by one or two ε4
alleles is only partially penetrant: ~50% of AD patients do
not carry an ε4 allele [5]. Application of quantitative
genetics methodology in fact supports the presence of 4 as
yet unidentified AD-associated loci in the human
genome, each expected to affect age of onset (AoO) as
much or more than APOE [6]. Additional genetic risk fac-
tors for AD, therefore, remain to be found. Yet, a majority
of studies have failed to find any evidence for association
of their genetic target(s) with AD (e.g., recently, Chapuis
et al. [7] and [8]), and large-scale meta-analyses, which
combine the datasets of numerous studies, often negate or
call into question any putative associations inferred from
individual datasets [9].
The disproportionate number of women who suffer from
AD has long suggested that an aspect of reproductive
physiology lies at the origin of AD pathogenesis. Recently,
this idea was supported by the discovery that polymor-
phisms of the estrogen receptors alpha and beta were asso-
ciated with AD, further implicating estradiol signaling in
the pathogenesis of AD [10,11]. Several converging lines
of evidence make another member of the hypothalamic-
pituitary-gonadal axis, luteinizing hormone (LH), a
worthwhile candidate for genetic study: (1) LH is elevated
in AD patients [12-14]; (2) LH crosses the blood-brain
barrier [15]; (3) in the brain, LH/chorionic gonadotropin
receptors (LHCGR) are most concentrated in the hippoc-
ampus [16]; (4) increased concentration of LH has been
shown to increase Aβ secretion in a neuronal cell line
while suppression of serum LH decreases brain Aβ in mice
[17]; and, (5) reduced serum LH has been shown to
decrease cognitive loss and Aβ deposition in AβPP trans-
genic mice [18]. Interestingly, through its regulation of
steroidogenic enzymes, LH mediates neurosteroid pro-
duction from cholesterol [19]; both animal and human
clinical studies strongly support the crucial neuroprotec-
tive functions of steroids in the brain [20,21]. Since APOE
is a cholesterol transport protein [22] involved in the
transport of cholesterol into neurons [23] for neuroster-
oid synthesis, a functional link exists between APOE and
LH signaling.
Numerous polymorphisms of LH beta-subunit (LHB) and
LHCGR  have been documented (for comprehensive
reviews, see [24] and [25]). While the majority of muta-
tions underlying these polymorphisms are associated
with rare reproductive disorders, a few are relatively more
common and worthy of exploring for their association
with AD. Two non-synonymous single nucleotide poly-
morphisms (SNPs) in LHB are collectively referred to as
variant LH (vLH) [26]. In a study of 40 Japanese women,
vLH carriers exhibited greater LH secretion in response to
GnRH stimulation [27]. In breast cancer patients, an LQ-
insert in exon 1 of LHCGR was associated with a signifi-
cantly earlier age of onset and worse survival rate [27].
Exon 10 of LHCGR is required for binding of LH [28] and
is the location of 2 relatively common non-synonymous
SNPs [29]. The functional consequences of the mutations
underlying the other LHB and LHCGR polymorphisms
scored in our study, however, are largely unknown. There-
fore, in this study we examined polymorphmic sites of LH
β-subunit (LHB) and LHCGR, as well as gene-gene inter-
actions between LHB, LHCGR, and APOE for association
with AD. Our results suggest that a specific LHCGR allele
significantly decreases the risk of AD in individuals carry-
ing an APOE ε4 allele.
Results
APOE  genotype and 14 previously reported polymor-
phisms of LHB and LHCGR were scored (Table 1). The A/
G polymorphism in exon 2 of LHB  (rs5030775) was
invariant and, therefore, not included in any analyses. The
2 SNPs comprising vLH (rs1800447) covaried without
fail, as did the LHB  polymorphisms rs2387588 and
rs4287687; in both instances, only one of the polymor-
phisms was subjected to analysis. Table 1 lists the names
assigned to the remaining 11 polymorphisms of LHB and
LHCGR.
Analysis of single-locus, main effects
HWE and AoO
The only locus demonstrating significant divergence from
HWE at the modified FDR level was lhcgr3 in the control
(C) group (AD: p = 0.052, C: p = 0.008; α = 0.0082). This
result is apparently driven by samples of the female con-
trol group (Cf; p = 0.034), as the male control group (Cm)
is not even marginally divergent from HWE (p = 0.149).
No main or interactive effects identified in our analyses
included lhcgr3. Only one genotype model was signifi-
cantly associated with age of onset (AoO) at the modified
FDR level. In the ADm group, AoO was affected by lhcgr2
genotype (Figure 1). Males with 1 or 2 C-alleles of lhcgr2
had a mean AoO of 81.06 years, while males with no C-
allele had a mean AoO of 78.33 (n = 50, p = 0.0047; α =
0.0077) – i.e., the C-allele significantly delays AoO in
males.BMC Medical Genetics 2008, 9:37 http://www.biomedcentral.com/1471-2350/9/37
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χ 2-tests for single-locus associations
Whether stratified by gender or not, no significant associ-
ations between LHB or LHCGR loci and AD were identi-
fied. As expected, the frequency of the APOE ε4 allele was
much greater in AD than in C samples: 0.35 and 0.09,
respectively. ε4 was also found at a higher frequency in
AD females (ADf; 0.39) than in AD males (ADm; 0.32).
Compared with ADm, a noticeably greater number of ε4
alleles were found in ADf heterozygotes (ε2/ε4 and ε3/ε4:
0.35 in ADm, 0.62 in ADf) than in homozygotes (ε4/ε4:
0.14 in ADm, 0.08 in ADf). A significant association, at
modified FDR levels, between the APOE ε4 allele and AD
was detected in AD vs. C (p < 0.0001; α = 0.0082), ADm
vs. Cm (p < 0.001; α = 0.0077), and ADf vs. C female (Cf;
p < 0.0001; α = 0.0081) comparisons. Both the 'ε4 dosage'
and 'ε4 positive' models of APOE genotype were associ-
ated with AD at marginally to highly significant levels in
AD vs. C (p < 0.0001; α = 0.0082), ADm vs. Cm (ε4 dos-
age: p = 0.003; ε4 positive: p = 0.007; α = 0.0077), and
ADf vs. Cf (p < 0.0001; α = 0.0081). The estimated OR
associated with ε4 was considerably higher in females ['ε4
dosage': 18.53 (6.18, 55.61); 'ε4 positive': 20.53 (6.80,
62.01)] than males ['ε4 dosage': 2.81 (1.36, 5.82); 'ε4 pos-
itive': 2.66 (1.14, 6.20).
Analysis of gene-gene interactions
LD analysis
In the ADm group but not the Cm group, significant
multi-locus LD at the modified FDR level was detected
between APOE and lhcgr2 (p = 0.003; α = 0.0077; Table
2), while a number of pairs of loci exhibited marginally
significant LD (p < 0.05; Table 2). Significant LD at the
modified FDR level was also detected between APOE and
lhcgr2 in Cf (p = 0.007; α = 0.0077; Table 2). A number of
LHCGR  loci in a number of different AD and control
groups were found to be in significant LD with several
LHB loci, especially lhb1 (Table 2).
APOE and LHB are closely linked to one another (chro-
mosomal region 19q13), separated by only 4.1 mega-
bases. We took great care to ensure that any associations
with AD observed in LHB were not the result of linkage
with APOE. The only instance of significant LD between
an LHB locus and APOE alone was found in the ADf and
total AD groups (lhb3, p < 0.0001 for both groups; α =
0.0081 and α = 0.0082, respectively). It is difficult to inter-
pret this result as an indication of LD that is simply due to
physical proximity of the loci, since none of the other LHB
loci exhibited even marginally significant LD with APOE.
Table 1: Scored polymorphisms of LHB and LHCGR.
Gene Designation dbSNP reference ID Location Type
LHB lhb1 rs3956233 Intron 1 Intronic SNP
lhb2 rs4002462 Intron 1 Intronic SNP
* rs5030775a Exon 2 (signal peptide) Non-synonymous SNP
lhb3 rs1800447 Exon 2 (vLH SNP 1) Non-synonymous SNP
** (rs1800447)b Exon 2 (vLH SNP 2) Non-synonymous SNP
lhb4 rs6521 Exon 2 Synonymous SNP
lhb5 rs1056914 Exon 2 Synonymous SNP
lhb6 rs2387588 Intron 2 Intronic SNP
lhb7 rs4287687 Intron 2 Intronic SNP
LHR lhcgr1 rs4539842 Exon 1 6 base insertion/deletion
lhcgr2 rs4073366 Intron 1 Intronic SNP
lhcgr3 rs12470652 Exon 10 Non-synonymous SNP
lhcgr4 rs2293275 Exon 10 Non-synonymous SNP
lhcgr5 rs13006488 Exon 11 Synonymous SNP
ars5030775 not included in analyses, as it was invariant in our cohort
bsecond vLH position not included in analyses since it is in complete linkage disequilibrium with lhb3
Age of onset is significantly affected by lhcgr2 genotype in  males Figure 1
Age of onset is significantly affected by lhcgr2 geno-
type in males. AoO in lhcgr2 heterozygous and 
homozygous males (n = 50, p = 0.001).
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lhb3 was not identified as a main effect, nor as a compo-
nent of any other significant interactions.
MDR analysis
MDR models were deemed significant when they met the
a priori significance criteria described in Methods. For the
AD vs. C comparison, one multi-locus combination was
significantly associated with AD: lhcgr1/lhcgr2/APOE was
selected as the best model in 6 of 10 cross-validation (CV)
runs and produced a training accuracy of >0.5 in 9 of 10
CV runs. Two multi-locus models exhibited significant
association with AD in the ADm vs. Cm comparison:
lhcgr2/APOE (8 of 10 CVs, >0.5 training accuracy in 7 of
10 CVs) and lhcgr2/lhcgr5/APOE (7 of 10 CVs, >0.5 train-
ing accuracy in 9 of 10 CVs). One multi-locus model,
lhb5/APOE (5 out of 10 CVs, >0.5 training accuracy in 10
of 10 CVs), was selected as significantly associated with
AD upon comparison of the ADf and Cf datasets. No sig-
nificant gene-gene interactions were detected using APOE-
free datasets.
LR analysis
LR analysis of the interactions suggested by LD and MDR
analyses supported two interactions as marginally signifi-
cant (lhcgr5/lhb2, both co-dominant, p = 0.05; lhcgr5/
lhb4, both co-dominant, p = 0.041) and one interaction
(lhcgr2/APOE) as significant at the modified FDR level.
The most significant combination of lhcgr2 and APOE
genotype models was the ε4-positive model of APOE and
the C-dominant model of lhcgr2 (p = 0.003). As illus-
trated in Figure 2, the OR associated with this interaction
[0.06 (0.01, 0.38)], represents a marked decrease in risk of
AD for males who possess 1 or 2 'C-alleles' for lhcgr2 and
are ε4-positive. Upon identification of this interaction we
sequenced lhcgr2 and APOE in 10 additional male (5C
and 5 AD) and 30 additional female (6C and 24 AD) sam-
ples. Use of the augmented datasets in LR analysis did not
change the p-value or OR associated with the male-spe-
cific interaction and the lhcgr2/APOE interaction was still
insignificant amongst females (p = 0.871).
Identification of a novel, missense mutation in LHCGR
Two males, one control and one AD, were heterozygous
for a previously unreported C->T (Arg->Stop) missense
mutation at the first position of codon 479 (exon 11) of
LHCGR (Figure 3).
Discussion
In general, our results suggest that putative associations
should be treated with caution if they do not receive con-
sistent support from biologically or statistically distinct
analyses or are discovered using only one analytic
method. Results of multiple analyses have the potential to
strengthen support for disease association, point to alter-
Table 2: Loci exhibiting pairwise linkage disequilibrium at p <= 0.05. Bold-faced loci indicate a combination detected at the α = 0.05 
level in an AD stratum but not in the corresponding control stratum. These multi-locus combinations were used as models in LR 
analyses.
Loci D' p-value Loci D' p-value
AD males lhcgr1/lhb1 0.576 0.029 Control males lhcgr1/lhb3 1.000 0.019
lhcgr1/lhb5 0.388 0.020 lhcgr1/lhb5 0.494 0.033
lhcgr2/APOE 1.000 0.002a lhcgr4/APOE 0.643 0.048
lhcgr5/lhb2 0.305 0.023 lhcgr5/APOE 0.746 0.047
lhcgr5/lhb4 0.293 0.033
lhcgr5/lhb5 0.335 0.028
AD females lhcgr2/APOE 0.520 0.032 Control females lhcgr1/lhb1 0.415 0.004b
lhb3/APOE 0.718 <0.0001b lhcgr1/APOE 0.281 0.031
lhcgr2/APOE 0.315 0.007b
All AD lhcgr1/lhb1 0.465 0.017 All Control lhcgr1/lhb1 0.352 0.006c
lhb3/APOE 0.540 <0.0001c lhcgr1/lhb2 0.419 0.021
lhcgr2/APOE 0.265 0.044
All males lhcgr1/lhb1 0.387 0.004a All females lhcgr1/lhb1 0.369 0.01a
lhcgr1/lhb2 0.301 0.047 lhcgr2/APOE 0.294 0.019
lhcgr1/lhb3 0.365 0.009a lhb3/APOE 0.296 0.041
lhcgr1/lhb4 0.312 0.038
lhcgr1/lhb5 0.458 0.001a
lhcgr1/lhb6 0.323 0.028
a significant at the corrected α = 0.0077 level (modified FDR) for the male dataset
b significant at the corrected α = 0.0082 level (modified FDR) for the female dataset
c significant at the corrected α = 0.0081 level (modified FDR) for the total dataset.BMC Medical Genetics 2008, 9:37 http://www.biomedcentral.com/1471-2350/9/37
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nate explanations of anomalous allele or genotype fre-
quencies, or disabuse one of the notion that a particular
polymorphism, unrelated to a disease of interest, plays a
central role in its etiology.
Multi-analytic approach to detection of gene-gene 
interaction
Studies that aim to identify genetic interactions are best
served by the multi-analytic approach to data analysis
practiced here and, for family-based data, by [30]. In the
absence of biochemical evidence, putative genetic interac-
tions are often difficult to accept intellectually. Multiple
lines of statistical support, which represent the identifica-
tion of a significant genetic interaction using different sta-
tistical and biological approaches, increase statistical and
intellectual confidence in the biological reality of an inter-
action. In this study, LR and MDR provided distinct statis-
tical/computational methods for the detection of
significant genetic interactions, while LD analysis pro-
vided a distinct biological approach to the problem of
interaction detection. A majority of AD-associated interac-
tions reported here lack intra-study corroboration, as they
were only identified by one analytical method (Table 3).
As such, these interactions are not well supported. On the
other hand, lhcgr2/APOE (the only interaction supported
by all 3 analytic methods at the modified FDR level) is a
better candidate for biochemical study. In addition, more
support for lhcgr2/APOE is derived from the association
of lhcgr2 with differences in AoO. The different analyses
are not, of course, statistically independent of one
another, as the same dataset is being analyzed in each
case. Nevertheless, because they are not independent, fail-
ure to identify the same interaction using distinct, robust
analytical methods seriously impugns the biological real-
ity of a putative interaction.
APOE, LH signaling, gender-specific effects, and AD
Polymorphisms of other HPG-axis proteins (estrogen
receptors α and β) are associated with increased suscepti-
bility to AD in women [10,11]. In this respect, prophylac-
tic and therapeutic use of natural estrogen (17β-estradiol)
has been consistently demonstrated to delay disease pro-
gression in women [11]. As LH signaling is directly
involved with reproduction, produces gender-specific
physiological and anatomical endpoints, and has been
associated with AD, LH and its receptor also present good
candidates for gender-specific associations with disease.
The male-specific nature of the significant lhcgr2/APOE
interaction identified in our analyses (Table 3), and its
relation to APOE  genotype, is important. Gender is
thought to interact with APOE genotype [31,32], and our
data support the hypothesis that the ε4 allele is more
strongly associated with female than male AD: 49% of
ADm and 70% of ADf were ε4 positive. If ε4 does provide
less explanatory power in males, it is logical to suggest
that male-specific risk factors for AD do exist. Indeed, one
recent study identified an association between number of
CAG repeats in the androgen receptor and AD [33].
Should further sampling corroborate the male-specific
association with AD of lhcgr2/APOE  (Table 3), it will
become imperative to elucidate the biochemical basis of
this gender bias (see discussion of the lhcgr2 site below).
While gender-specific hormonal fluctuations, namely the
rise in LH serum levels following menopause, have been
suggested to account for the disproportionately greater
number of females who acquire AD [34,35], the idea that
common differences in the actual sequence and structure
of LHβ and its receptor might only affect males is intrigu-
ing. We can exclude issues related to genetic or trait heter-
ogeneity as explaining our results since all scored loci
exhibit HWE in males and the dataset is consistent with
past sampling of APOE genotype in males. ε2, ε3, and ε4
allele frequencies among affected males in our study were
Risk associated with ε4 allele is negated in male, lhcgr2 heter- ozygotes Figure 2
Risk associated with ε4 allele is negated in male, 
lhcgr2 heterozygotes. Contingency table illustrating the 
relative frequencies of lhcgr2/APOE genotypes in males and 
females (black = AD; white = Control).
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0.03, 0.66, and 0.32, respectively, which are not obviously
different from those reported in a meta-analysis of 5107
case-control Caucasian AD subjects (4): 0.039 (ε2), 0.594
(ε3), and 0.367 (ε4). 49% of ADm and 70% of ADf were
ε4-positive in our study, which is strikingly similar to the
46.6%  ε4-postive males and 72% ε4-positive females
reported in a previous paper suggesting interaction
between gender and APOE genotype (36). Additionally,
neither mean age (83.34 +/- 5.14 yrs in males, 83.34 +/-
5.58 yrs in females; p = 1.00) nor mean AoO (79.18 +/-
3.47 yrs in ADm and 80.26 +/- 5.07 yrs in ADf; p = 0.22)
were significantly different in males and females. Docu-
mented instances of alcohol and drug use, cardiovascular
disease, and stroke were equally rare in males and females
of our cohort.
Despite strong support for the association between
lhcgr2/APOE and AD, the details of the interaction are
paradoxical. While the ε4 allele carried significant risk of
AD in males of our dataset (p = 0.007), males who carried
1 or 2 C-alleles at the lhcgr2 locus and were ε4 positive
had a significantly reduced risk of AD (odds ratio: 0.04;
95% confidence level: 0.01, 0.32; p = 0.002). As both
increased LH levels [17] and the APOE ε4 allele [36,37]
are associated with increased Aβ deposition, and neuros-
teroid production, it is reasonable to suggest that LH sig-
naling and APOE  genotype interact to modify an
individual's susceptibility to AD. The significant decrease
in risk of AD observed in ε4-positive males with 1 or 2
lhcgr2 C-alleles lends support to the possibility that
lhcgr2-dependent alternative splicing of LHCGR  pre-
mRNA leads to isoforms of LHCGR that are functionally
distinct (see below), or that lhcgr2 is part of an intron-
derived microRNA (miRNA) capable of regulating APOE
mRNA translation (see below). Despite the absence of
empirical evidence to support the existence of unreported
LHCGR isoforms or miRNAs derived from LHCGR
introns, our data do support a complex, gender-specific
interaction between LHCGR and APOE. Of note, LH ele-
vates APOE secretion from cultured interstitial cells,
thereby increasing the availability of cholesterol for sex
hormone production [38]. LH also increases low-density-
lipoprotein receptor-related protein expression in granu-
lose cells [39]. If such processes occur in the brain, then
the protective effects of an LHCGR-APOE interaction in
males may be mediated via increased neurosteroid pro-
duction and the male-specific nature might be explained
by differential protective effects of androgens and estro-
gens.
Intronic polymorphisms and lhcgr2 as a cryptic splice site 
or intron-derived miRNA
The most significant interaction associated with AD in this
study includes lhcgr2, a polymorphism located in intron
Novel missense mutation in exon 11 of LHCGR Figure 3
Novel missense mutation in exon 11 of LHCGR. (A) Chromatogram from one of two samples heterozygous for a novel 
C->T (Arg->Stop) missense mutation in codon 479 (exon 11) of LHCGR. (B) Chromatogram from a sample homozygous for 'C' 
at the same site.
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1 of LHCGR. Intronic polymorphisms are frequently
implicated in increased disease susceptibility [11,40,41]
and intronic mutations have the potential to alter protein
sequence dramatically. An intronic mutation can cause
the disarrangement of an existing splice site or introduce
a cryptic splice site, resulting in the addition/removal of
hundreds of amino acids or premature termination of
translation. A second mechanism by which intronic muta-
tions might affect disease etiology is through their effect
on the miRNAs that may be derived from the mutated
intron. ~10–30% of spliced intronic material is exported
to the cytoplasm, where it has the potential to act as an
miRNA and alter protein expression [42]. It follows that
mutation of intronic sequence could decrease or increase
the complementarity of an intron-derived miRNA to its
target mRNA, thereby causing a relative decrease or
increase in expression of the encoded protein. Indeed the
15 bases immediately upstream of lhcgr2 are complemen-
tary to APOE mRNA (Figure 4A), indicating this polymor-
phism may cap an intron-derived miRNA.
Examination of the sequence surrounding lhcgr2 and
alignment of human and mouse (Mus musculus) LHCGR
intron 1 indicate lhcgr2 may be located within a cryptic 3'
acceptor splice site (Figure 4B). Acceptor splice sites are
characterized by two conserved sequence patterns: a pyri-
midine-rich sequence, known as the polypyrimidine tract,
and the proximate terminal 'AG' of the intron [43].
Although the length of the polypyrimidine tract and its
distance from the end of the intron are variable, the termi-
nal 'AG' is invariant [43,44]. Polymorphism lhcgr2 is
located within a pyrimidine-rich region of intron 1 (Fig-
ure 4B). The lhcgr2 'C-allele' increases the CT-content of
the surrounding 19 nucleotides to 79%, and, more
locally, a 'C' at lhcgr2 forms a contiguous sequence of 7 Cs
and Ts. Four bases downstream of this pyrimidine-rich
tract is a 3' acceptor site consensus sequence, CAGG.
Absence of a homologous sequence in mouse LHCGR
intron 1 may indicate that retention of this sequence in
Homo sapiens is due to its potential use in alternative splic-
ing. To investigate the degree to which a 'C' at lhcgr2
increases the similarity of the local sequence to human
acceptor sites in general, lhcgr2 'C' and 'G' alleles were
entered in the online splice site prediction programs
GENIO/splice and SpliceScan [45]. Both programs identi-
fied lhcgr2 as a potential acceptor splice site and, based on
the programs' output scores, indicated that a 'C' at the site
does increase its similarity to stereotyped 3' acceptor
splice sites.
Linkage disequilibrium between lhcgr1 and multiple LHB 
loci
LD between lhcgr1 and LHB loci was commonly detected
in several AD and C datasets (Table 2), including 6
instances in the 'All male' dataset. The frequent identifica-
tion of LD between lhcgr1 and LHB loci indicates that spe-
Table 3: Distribution of significant associations between non-APOE polymorphisms and AD. LD = linkage disequilibrium, MDR = multi-
dimensionality reduction, LR = logistic regression, AoO = age of onset,      = significant at the modified FDR α level, or, in the case of 
MDR, according to a priori significance criteria: for significant MDR results, the proportion of 10 CVs that identified this model as best 
and proportion of 10 CVs in which this model produced a training accuracy >0.5 are listed;    = approaching significance (p <= 0.05, the 
experimentwise α). Note the consistent identification of lhcgr2/APOE as a significant interaction in males. CV = cross-validation.
Loci Dataset χ2 AoO LD MDR LR
lhb2  ●
lhcgr2  ●●
(p = 0.001; α = 0.0077)
lhcgr1/lhb1  ●
lhcgr1/lhb5  ●
lhcgr2/APOE  ●●
(p = 0.002; α = 0.0077)
●●
(0.8 CVs; 0.7 CVs)
●●
(p = 0.003; α = 0.0077)
lhcgr5/lhb2  ●●
lhcgr5/lhb4  ●●
lhcgr5/lhb5  ●
lhcgr2/lhcgr5/APOE  ●●
(0.7 CVs; 0.9 CVs)
lhcgr2/APOE  ●
lhb3/APOE  ●●
(p < 0.0001; α = 0.0081)
lhb5/APOE  ●●
(0.5 CVs; 1.0 CVs)
lhcgr1/lhb1 Total ●
lhb3/APOE Total ●●
(p < 0.0001; α = 0.0082)
lhcgr1/lhcgr2/APOE Total ●●
(0.6 CVs; 0.9 CVs)BMC Medical Genetics 2008, 9:37 http://www.biomedcentral.com/1471-2350/9/37
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cific  LHB  haplotypes are found most frequently in
individuals that are hetero- or homozygous for the LQ-
insertion at lhcgr1. We questioned whether our data sup-
ported the idea that the LQ-insertion at lhcgr1 is, in gen-
eral, in LD with LHB loci. To examine this possibility, we
compared the frequency of genotypes at all 6 LHB loci
between individuals with no LQ-inserts and those with 1
or 2 LQ-inserts (Figure 5). In both the group of all males
and the group of all samples, χ2-tests revealed that the gen-
otype counts of a majority of LHB loci were markedly dif-
ferent from one another in the LQ-insert and no-LQ-insert
strata (Figure 5). This suggests: (1) a non-random force,
such as selection, is driving the non-random association
of LQ-insert alleles with specific LHB haplotypes in the
North American Caucasian population – i.e., certain vari-
ants of LHB may be better suited to the LQ-insert variant
of LHCGR; (2) given the extent of LD between lhcgr1 and
LHB loci in C and AD samples, instances of significant LD
between lhcgr1 and LHB loci in AD samples are not indic-
ative of AD-associated interactions.
Methods
Case-control setup
The National Cell Repository for Alzheimer's Disease
(NCRAD; University of Indiana, Bloomington, IN) pro-
vided total DNA samples from 200 control (negative for
AD and other neurodegenerative diseases, 50 male and 50
female) and late-onset AD patients (negative for other
neurodegenerative diseases, 50 male and 50 female). All
samples were obtained from North American Caucasian
subjects. All samples were derived from individuals >= 75
years of age, and all AD samples were acquired from indi-
viduals whose AoO was = 75. Mean age of the control
group was 84.73 w 4.61 years, while mean age of the AD
group was 81.95 ± 5.69 years. Among the AD samples,
AoO was 79.18 ± 3.47 years for males and 80.26 ± 5.07
years for females. DNA was obtained from 40 additional
samples (10 male samples – 5 control, 5 AD and 30
female samples – 6 control, 24 AD) to test for significant
interaction between APOE and an LHCGR locus (lhcgr2,
see below). Direct sequencing of APOE, LHB (promoter,
signal, and coding regions), and LHCGR (exons 1, 10, and
11) was performed using the primer pairs listed in Table
4. Cycle sequencing products were run on an ABI 3730 XL
DNA analyzer at the University of Wisconsin Biotechnol-
ogy Center (Madison, WI) and the resultant chromato-
grams were analyzed with FinchTV v1.4 (Geospiza,
Seattle, WA). This study was carried out with IRB approval
from the Health Sciences Institutional Review Board of
the University of Wisconsin.
Data analysis
Similar to the analytic paradigm suggested by [30] for fam-
ily-based data, we chose to analyze our case-control dataset
using an array of analytic methods, testing for interactive
as well as main effects, and treating the convergence of
results from distinct analyses as the best evidence of asso-
ciation. Allele and genotype counts were used in the fol-
lowing analyses: (1) χ2 tests of allele and genotype counts
to test for main effects of individual polymorphisms; (2)
tests of each locus for Hardy-Weinberg Equilibrium
(HWE); (3) tests of combinations of two or three loci for
linkage disequilibrium (LD); (4) tests for gene-gene inter-
actions using multifactor dimensionality reduction
(MDR); (5) tests for interactions using logistic regression
(LR), and; (6) tests for association of polymorphisms with
age of onset using one-way ANOVA. Additionally, to con-
trol for heterogeneity we stratified the dataset according to
gender and applied the same 6 analyses. Finally, for each
lhcgr2 shares similarity with consensus 3' acceptor splice  sites and ApoE mRNA Figure 4
lhcgr2 shares similarity with consensus 3' acceptor 
splice sites and ApoE mRNA. (A) lhcgr2 as a potential 
miRNA that regulates the expression of ApoE. The reversed 
LHCGR sequence is complimentary to a fragment of APOE 
mRNA at 13 out of 16 sites. (B) Pairwise sequence alignment 
of a portion of LHR intron 1 in human and mouse (Mus mus-
culus). The human sequence includes lhr2 (rs4073366) and 
bears sequence features characteristic of 3' acceptor splice 
sites.BMC Medical Genetics 2008, 9:37 http://www.biomedcentral.com/1471-2350/9/37
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bi-allele locus, four genotype models were analyzed in
tests for interactive effects: co-dominant, allele 1 domi-
nant, allele 2 dominant, and over-dominant. This schema
enabled us to: (1) address the possibility of heterozygote
advantage, and; (2) test both alleles for dominance, as we
had no a priori knowledge of which allele might carry risk.
For each sample, genotype and demographic data were
entered into a MySQL relational database, enabling the
quick identification of samples meeting an array of crite-
ria. APOE genotype and 14 previously reported polymor-
phisms of LHB  and  LHCGR  were scored. For each
polymorphism, allele and genotype frequencies of the AD
and control groups were calculated. Additionally, both
groups were stratified by gender and gender-specific allele
and genotype frequencies were calculated. Four separate
genotype models were used in tests for main and interac-
tive effects of bi-allele loci. For example, the following
models would be used for a locus that varied between alle-
les B and b: (1) co-dominant (BB vs. Bb vs. bb); (2) B
dominant [(BB + Bb) vs. bb]; (3) b dominant [BB vs. (Bb
+ bb)], and; (4) over-dominant [(BB + bb) vs. Bb]. For the
tri-allele APOE, an 'ε4 dosage' model (genotypes grouped
by the number of ε4 alleles) and an 'ε4 positive' model (ε4
allele present or not) were used in analyses.
The program Genetic Data Analysis (GDA) [46] was used
to test each polymorphic locus for HWE. Minitab [47] was
used to test for the association of individual polymor-
phisms with AD (χ2 tests of allele and genotype counts)
and AoO in the AD groups (ANOVA). In all tests for LD,
genotypes were preserved in order to prevent significant
deviations from HWE at a single locus from contributing
to the measure of LD. We considered a number of theoret-
ical issues when designing our analytical approach to
detect gene-gene interactions (see Supplementary Infor-
mation) and ultimately chose the combination of LD,
MDR and LR analyses. Pairwise tests for LD were per-
formed using the program PyPop, where the p-value
reported here is derived from the difference between the
likelihood of the inferred haplotype frequencies and the
likelihood of the data if the two loci are assumed to be in
linkage equilibrium [48]. We reported the D' measure of
LD, as this is an intuitive metric that represents the esti-
mated proportion of maximum possible LD exhibited by
the sample data. MDR was performed using MDR Soft-
ware [49], which output the best 1-, 2-, 3-, and 4-factor
models for a given dataset. 10-fold cross-validation was
used. Given the weight APOE carries as a single factor,
MDR was also run using APOE-free datasets in order to
detect any interactions that did not include APOE. An
interaction model was considered significant if it was
selected as the best model in 5 or more of the CV runs and
exhibited a testing accuracy of >0.5 in 7 or more CV runs.
Pairs of loci exhibiting significant LD (p <= 0.02) and sig-
nificant multi-locus models discovered using MDR were
input as disease models in LR analyses performed in [47].
This form of LR model selection was necessary, as a lack of
several multi-locus combinations made backward model
selection impossible and the lack of significant main
effects in most loci studied made forward model selection
impractical.
To account for multiple tests, testwise α levels were cor-
rected using modified FDR (see Supplementary Informa-
tion). Because a multi-locus combination was only tested
with LR if LD and/or MDR analyses were suggestive of its
association with AD, only a subset of the total array of
possible LR tests were actually performed and the total,
male, and female datasets were subjected to a different
total number of tests: 182, 252, and 190 tests, resulting in
modified FDR α levels of 0.0082, 0.0077, and 0.0081,
respectively.
Conclusion
We report the discovery of a genetic interaction between
APOE and LHCGR alleles that is associated with a signifi-
cantly decreased risk for AD in males. The biochemical
basis for this interaction is uncertain, although alternative
mRNA splicing and intron-derived miRNA regulation are
hypothesized as distinct possibilities. Our results empha-
size the importance of testing for gene-gene interactions
in studies of complex disease. We suggest that the best evi-
dence for epistasis is obtained when multiple analyses,
distinct in their biological or statistical basis, converge on
a positive result.
Appendix
Methodological strategies for the detection of gene-gene 
interactions
We searched for genetic association of single loci with AD
using standard χ2 and HWE tests and considered that sub-
sequent tests for gene-gene interactions may identify
interactions whose loci may or may not produce signifi-
cant main effects on their own. There are a number of ana-
lytical issues to consider when searching for multiple
interacting genetic (or environmental) factors associated
with a disease of complex etiology. For one, genetic or
trait heterogeneity among the samples (e.g., AD samples
from males or females, or, with or without hypertension)
has the potential to confound data analysis. Stratification
of the dataset is the most straightforward method used to
control for heterogeneity. For example, one might exam-
ine the effects of APOE heterogeneity by splitting control
and AD groups into ε4 positive and negative strata and
asking: Is the frequency of an SNP of interest significantly
higher in ε4-positive AD samples than in ε4-positive con-
trols, but not in the comparable ε4-negative comparison?
If so, the data suggest an interactive effect between the
SNP and ε4. Significantly, a non-stratified comparison ofBMC Medical Genetics 2008, 9:37 http://www.biomedcentral.com/1471-2350/9/37
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AD and control groups in such a case might lead a
researcher to conclude the SNP has no association with
AD, or, conversely, that the SNP is associated with AD in
ε4 positive and negative individuals. Though more math-
ematical methods to control for heterogeneity exist, the
majority of them are not applicable to case-control data.
In studying the genetics of a complex disease, it is impor-
tant to consider the possibility that gene-gene or gene-
environment interactions produce interactive effects that
provide significant explanatory power, even in the
absence of single factor, main effects [53]. A number of
methods allow researchers to test for gene-gene interac-
tions using case-control data. A traditional method is
logistic regression (LR), which, given a dataset, models the
probability of a discrete outcome (in our case, AD or not)
on n factors and their interactions, each qualified by a
coefficient estimated using Maximum Likelihood Estima-
tion. Attractively, LR produces an Odds Ratio (OR), which
provides the researcher with an intuitive measure of how
a particular array of genetic and/or environmental factors
affects the likelihood of developing the disease. The major
shortcoming of LR is the so-called 'curse of dimensional-
ity', which refers to poor coefficient estimation resulting
from too few or no examples of various multi-factor com-
binations in the dataset if sample size is too small or
number of factors too large [54].
An alternative to LR analysis for the detection of interac-
tions is multifactor dimensionality reduction (MDR) [55],
which is advantageous for several reasons. A chief, practi-
cal advantage is that the researcher can easily test disease
models that include interaction terms whose components
lack significant main effects. This is critical, since it is
Significant linkage disequilibrium between lhcgr1 and multiple LHB loci Figure 5
Significant linkage disequilibrium between lhcgr1 and multiple LHB loci. In the schematic of LHB, exons are repre-
sented as black boxes and the positions of the 7 LHB polymorphisms scored are indicated by vertical lines. lhb3 is composed of 
two SNPs, which are in complete LD with each other. For each polymorphism, genotype frequencies are represented in the 
form of two pie charts, where the left chart represents genotype frequencies among individuals lacking an LQ-insert allele in 
exon 1 of LHCGR (lhcgr1) and the right chart represents genotype frequencies among individuals possessing 1 or 2 LQ-insert 
alleles. Frequencies above the graphs correspond to AD males, while frequencies below the graph correspond to all individuals 
sampled in this study. * = significant difference (p < 0.05), ** = highly significant difference (p < 0.01).
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increasingly apparent that genetic interactions, in the
absence of main effects, frequently contribute to the sus-
ceptibility of an individual to complex diseases like AD
[56]. Also important, MDR is not "cursed" by dimension-
ality: the method is robust even when the input dataset
lacks examples of various, multi-factor combinations.
Finally, unlike LR, MDR analysis automatically measures
the predictive accuracy and validity of a selected model
through partitioning of the original dataset into training
and testing subsets [57,58].
Another approach to gene-gene interaction detection is to
calculate linkage disequilibrium (LD) amongst combina-
tions of the loci under investigation. Significant LD
among 2 or more loci indicates non-random segregation
of the loci in question, which implies that at least one
multi-allele combination at these loci is overrepresented.
Logically, any multi-allele combination enriched in the
case but not the control group is considered to contribute
increased susceptibility to the disease, and is reflected by
a measurement of significant LD in the case group only
[59]. Williams et al. [60] used this approach in a study of
polymorphisms associated with hypertension, discover-
ing 16 combinations of 7 loci in 5 genes that exhibited sig-
nificant LD in the case group only. Significantly, none of
these loci were associated with a main effect on hyperten-
sion, indicating LD analysis has the ability to detect
potentially significant gene-gene interactions in the
absence of main effects.
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